Amneal Appoints Jeff George, John Kiely and Shlomo Yanai to Board of Directors Three Independent Directors Bring Significant Pharmaceutical, Healthcare and Financial Expertise and Track Records of Creating Value for Shar

Amneal Appoints Jeff George, John Kiely and Shlomo Yanai to Board of Directors

Three Independent Directors Bring Significant Pharmaceutical, Healthcare and Financial Expertise and

Track Records of Creating Value for Shareholders

BRIDGEWATER, N.J. December 16, 2019 Amneal Pharmaceuticals, Inc. (NYSE: AMRX) ( Amneal or the Company ) today

announced that Jeff George, John Kiely and Shlomo Yanai have been appointed to the Company s Board of Directors, effective as of December 14, 2019. These three new independent directors bring to Amneal extensive records of overseeing

growth and creating value in the pharmaceutical and healthcare industries.

Paul Meister, Chairman of Amneal s Board, said, It is a testament

to the opportunities ahead for Amneal that we have attracted leaders of Jeff, John and Shlomo s caliber to our Board. They each have deep knowledge of our industry, and we are confident they will help us capitalize on those opportunities.

Moving forward, we will continue to add new expertise and fresh perspectives to our Board.

Co-Founders and Co-Chief Executive Officers, Chirag Patel and Chintu Patel, said, Jeff, John and Shlomo each bring tremendous records of leadership and delivering

results in the global pharmaceutical and healthcare industries, and we are pleased to welcome them to the Amneal Board. We look forward to working closely with them as we execute on our strategies to reinvigorate Amneal, drive growth and create

value for patients, shareholders and our other stakeholders.

Select leadership and industry experience for Amneal s three new directors

Amneal also announced today that Jean Selden Greene has retired from the Amneal Board, effective as of

December 14, 2019. Ms. Greene s resignation was not based on any disagreement with the Company on any matter relating to the Company s operations, policies or practices. As a result of the foregoing changes on Board composition,

the Board will comprise eleven directors.

Amneal Pharmaceuticals, Inc. (NYSE: AMRX), headquartered in Bridgewater, NJ, is a fully-integrated pharmaceutical company focused on the development,

manufacture and distribution of generic and specialty drug products. The Company has manufacturing operations in North America, Asia, and Europe, working together to bring high-quality medicines to patients primarily within the United States.

Amneal has an extensive portfolio of more than 225 marketed commercial products and is expanding its portfolio to include complex dosage forms, including

biosimilars, in a broad range of therapeutic areas. The Company also markets a portfolio of branded pharmaceutical products through its Specialty segment focused principally on central nervous system and endocrine disorders. For more information,

visit www.amneal.com.

Forward-Looking Statements

Certain statements contained herein, regarding matters that are not historical facts, may be forward-looking statements (as defined in the Private Securities

Litigation Reform Act of 1995, as amended). Such forward-looking statements include statements regarding management s intentions, plans, beliefs, expectations or forecasts for the future, including, among other things, future operating results

and financial performance, product development and launches, integration strategies and resulting cost reduction, market position and business strategy. Words such as may, will, could, expect,

plan, anticipate, intend, believe, estimate, assume, continue, and similar words are intended to identify estimates and forward-looking statements.

The reader is cautioned not to rely on these forward-looking statements. These forward-looking statements are based on current expectations of future events.

If the underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Amneal. A list and descriptions of these risks, uncertainties and

other factors can be found in the Company s most recently filed Annual Report on Form 10-K for the fiscal year ended December 31, 2018, as supplemented by any subsequently filed Quarterly Reports on

Form 10-Q. Copies of these filings are available online at www.sec.gov, www.amneal.com or on request from the Company.

Forward-looking statements included herein speak only as of the date hereof and we undertake no obligation to revise or update such statements to reflect the

occurrence of events or circumstances after the date hereof, except as otherwise required by United States securities laws.

Chief Financial Officer